Jeffry Keyes - QuantumSi Chief Officer
| QSI Stock | USD 1.14 0.09 7.32% |
Executive
Jeffry Keyes is Chief Officer of QuantumSi
| Age | 51 |
| Address | 29 Business Park Drive, Branford, CT, United States, 06405 |
| Phone | 866 688 7374 |
| Web | https://www.quantum-si.com |
Jeffry Keyes Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffry Keyes against QuantumSi stock is an integral part of due diligence when investing in QuantumSi. Jeffry Keyes insider activity provides valuable insight into whether QuantumSi is net buyers or sellers over its current business cycle. Note, QuantumSi insiders must abide by specific rules, including filing SEC forms every time they buy or sell QuantumSi'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffry Keyes over six months ago Acquisition by Jeffry Keyes of 50000 shares of QuantumSi at 1.61 subject to Rule 16b-3 |
QuantumSi Management Efficiency
The company has Return on Asset of (0.2283) % which means that on every $100 spent on assets, it lost $0.2283. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3579) %, meaning that it generated no profit with money invested by stockholders. QuantumSi's management efficiency ratios could be used to measure how well QuantumSi manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.34. The current Return On Capital Employed is estimated to decrease to -0.41. As of now, QuantumSi's Net Tangible Assets are increasing as compared to previous years. The QuantumSi's current Non Currrent Assets Other is estimated to increase to about 729.8 K, while Total Assets are projected to decrease to under 279.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Anderson | Crispr Therapeutics AG | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| Eric Mosbrooker | Avidity Biosciences | 57 | |
| Linea Aspesi | Editas Medicine | 54 | |
| John III | Avidity Biosciences | 66 | |
| MS MBA | Alector | 49 | |
| Brett Fleshman | Heron Therapeuti | N/A | |
| Kristina MPH | Alector | N/A | |
| Susan Kim | Crispr Therapeutics AG | N/A | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Allan MD | Prime Medicine, Common | 49 | |
| Norah Conway | Alector | N/A | |
| Karen JD | Prime Medicine, Common | N/A | |
| Asim Siddiqui | Seer Inc | N/A | |
| W Flanagan | Avidity Biosciences | 61 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Stuart Henderson | Passage Bio | N/A | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
| Katie Hogan | Alector | N/A | |
| Manmohan Singh | Beam Therapeutics | N/A | |
| Gary MD | Alector | 62 | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.23 |
QuantumSi Leadership Team
Elected by the shareholders, the QuantumSi's board of directors comprises two types of representatives: QuantumSi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of QuantumSi. The board's role is to monitor QuantumSi's management team and ensure that shareholders' interests are well served. QuantumSi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, QuantumSi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Rearick, Chief Officer | ||
| Katherine Atkinson, Senior Brand | ||
| Todd Bennett, Chief Officer | ||
| Michael McKenna, Exec Operations | ||
| Claudia Drayton, Chief Officer | ||
| Jeffry Keyes, Chief Officer | ||
| Jeffrey Hawkins, CEO President | ||
| Juan Avendano, Vice Relations | ||
| Alex Hutcheson, Senior Service | ||
| John Vieceli, Chief Officer | ||
| Jonathan Rothberg, Founder Chairman | ||
| Patrick Schneider, Pres COO | ||
| Grace Johnston, Chief Officer | ||
| Jeffry CPA, CFO Treasurer | ||
| Johan Denecke, Senior Operations | ||
| Christian JD, General Secretary |
QuantumSi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is QuantumSi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (35.69) % | ||||
| Current Valuation | (19.83 M) | ||||
| Shares Outstanding | 122.78 M | ||||
| Shares Owned By Insiders | 19.85 % | ||||
| Shares Owned By Institutions | 36.00 % | ||||
| Number Of Shares Shorted | 5.14 M | ||||
| Price To Earning | 5.15 X | ||||
| Price To Book | 0.77 X |
Currently Active Assets on Macroaxis
When determining whether QuantumSi offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of QuantumSi's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Quantumsi Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Quantumsi Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in QuantumSi. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in QuantumSi Stock please use our How to Invest in QuantumSi guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of QuantumSi. If investors know QuantumSi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about QuantumSi listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.016 | Quarterly Revenue Growth 2.529 | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of QuantumSi is measured differently than its book value, which is the value of QuantumSi that is recorded on the company's balance sheet. Investors also form their own opinion of QuantumSi's value that differs from its market value or its book value, called intrinsic value, which is QuantumSi's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because QuantumSi's market value can be influenced by many factors that don't directly affect QuantumSi's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between QuantumSi's value and its price as these two are different measures arrived at by different means. Investors typically determine if QuantumSi is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, QuantumSi's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.